Literature DB >> 1701371

Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome.

G S Conway1, H S Jacobs, J M Holly, J A Wass.   

Abstract

This study explores the clinical and endocrine implications of hyperinsulinaemia in the polycystic ovary syndrome (PCOS). Oral glucose tolerance tests were performed on 34 lean and 19 obese women with PCOS and on 13 lean women with normal ovaries. Insulin measurements were compared with basal gonadotrophins, androgens, insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein 1 (IGFBP-1). Unselected lean women with PCOS were found to have fasting hyperinsulinaemia and the raised serum insulin concentrations were associated with menstrual disturbance and hyperandrogenaemia. In addition, serum insulin concentrations in lean women with PCOS correlated positively with serum IGF-I and negatively with serum IGFBP-1 concentrations. Ovarian stimulation by insulin appears to be independent of luteinizing hormone (LH) and is an important feature in 30% of lean women with PCOS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701371     DOI: 10.1111/j.1365-2265.1990.tb03897.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

2.  Effects of growth hormone on in vitro maturation of germinal vesicle of human oocytes retrieved from small antral follicles.

Authors:  H A Hassan; H Azab; A A Rahman; T M Nafee
Journal:  J Assist Reprod Genet       Date:  2001-08       Impact factor: 3.412

3.  Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels.

Authors:  G Tropeano; I P Vuolo; A Lucisano; L Liberale; A Barini; P Carfagna; G Caroli; E Menini; S dell'Acqua
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

4.  Expression and clinical significance of the HIF-1a/ET-2 signaling pathway during the development and treatment of polycystic ovary syndrome.

Authors:  Fan Wang; Zhenghong Zhang; Zhaokai Wang; Kaizhuan Xiao; Qing Wang; Jingqian Su; Zhengchao Wang
Journal:  J Mol Histol       Date:  2015-01-23       Impact factor: 2.611

Review 5.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

Review 6.  Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style?

Authors:  J Holte
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

7.  A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum.

Authors:  T T Chiu; P P Tam
Journal:  J Assist Reprod Genet       Date:  1992-12       Impact factor: 3.412

8.  Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.

Authors:  Eloise Fraison; Elena Kostova; Lisa J Moran; Sophia Bilal; Carolyn C Ee; Christos Venetis; Michael F Costello
Journal:  Cochrane Database Syst Rev       Date:  2020-08-13

9.  Effect Of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystıc ovary syndrome.

Authors:  Muammer Karadeniz; Mehmet Erdoğan; Zengi Ayhan; Murat Yalcin; Murat Olukman; Sevki Cetinkalp; Gulinnaz E Alper; Zuhal Eroglu; Asli Tetik; Vildan Cetintas; Ahmet G Ozgen; Fusun Saygili; Candeger Yilmaz
Journal:  Lipids Health Dis       Date:  2011-10-28       Impact factor: 3.876

10.  Bone mineral density in women with polycystic ovary syndrome.

Authors:  K Katulski; S Slawek; A Czyzyk; A Podfigurna-Stopa; K Paczkowska; N Ignaszak; N Podkowa; B Meczekalski
Journal:  J Endocrinol Invest       Date:  2014-09-23       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.